product name STF-31
Description: STF-31 is a potent and selective glucose transporter GLUT1 inhibitor. STF31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. Treatment with STF31 inhibits the growth of RCCs by binding GLUT1 directly and impeding glucose uptake in vivo without toxicity to normal tissue. STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures.
References: Sci Transl Med. 2011 Aug 3;3(94):94ra70; ACS Chem Biol. 2014 Oct 17;9(10):2247-54; Stem Cell Reports. 2014 Jun 6;3(1):185-203.
423.53
Formula
C23H25N3O3S
CAS No.
724741-75-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 85 mg/mL (200.7 mM)
Water: <1 mg/mL
Ethanol: 25 mg/mL (59.0 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: STF-31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1. STF-31 significantly inhibits lactate production and extracellular acidification in VHL-deficient cells by about 60%, and decreases glycolysis by decreasing glucose transport. In NAPRT1-expressing cells, STF-31 shows cytotoxicity by inhibiting the enzymatic activity of NAMPT. STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In mice with VHL-deficient RCC xenografts, a more soluble analog of STF-31 (11.6 mg/kg, i.p.) markedly delays tumor growth. |
| Animal model | Mice with VHL-deficient RCC xenografts |
| Formulation & Dosage | Dissolved in DMSO in 16% cremophor EL/PBS; 11.6 mg/kg; i.p. injection |
| References | Sci Transl Med. 2011 Aug 3;3(94):94ra70; ACS Chem Biol. 2014 Oct 17;9(10):2247-54; Stem Cell Reports. 2014 Jun 6;3(1):185-203. |
